Repligen
RGEN
#2045
Rank
โ‚น834.85 B
Marketcap
โ‚น14,831
Share price
-0.47%
Change (1 day)
23.07%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of September 2025 : โ‚น61.92 Billion

According to Repligen 's latest financial reports the company's total debt is โ‚น61.92 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚น58.87 B-0.65%
2023-12-31โ‚น59.25 B69.31%
2022-12-31โ‚น35.00 B28.46%
2021-12-31โ‚น27.24 B35.27%
2020-12-31โ‚น20.14 B7.27%
2019-12-31โ‚น18.77 B159.5%
2018-12-31โ‚น7.23 B14.19%
2017-12-31โ‚น6.33 B-2.12%
2016-12-31โ‚น6.47 B
2005-03-31โ‚น5.21 M40.38%
2004-03-31โ‚น3.71 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novavax
NVAX
โ‚น22.57 B-63.54%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚น54.31 B-12.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚น38.51 B-37.81%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚น1.873 T 2,924.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚น3.207 T 5,079.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น4.588 T 7,309.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น5.469 T 8,733.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚น35.46 B-42.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚น2.28 B-96.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚น236.30 B 281.59%๐Ÿ‡บ๐Ÿ‡ธ USA